Here's an excerpt from recent article.
Lpath Inc. ( LPTN.OB), the industry leader in lipidomics-based antibody therapeutics, has announced the initial dosings of two proof-of-concept trials over the past few months, with results from both trials due to be announced in 2012.
The two trials, PEDigree and Nexus, will measure Lpath's iSONEP as a treatment for retinal pigment epithelium detachment ("RPE detachment" or "PED") and Wet AMD, respectively. Phase I trials have already proven that treatment with iSONEP was well tolerated in all subjects, while demonstrations of efficacy were also noted.
It's not only the unique approach of bioactive lipid technology that Lpath brings to the table that is quickly attracting investor attention, but a high-profile partnership with powerhouse Pfizer ( PFE) has also put this company and its stock on the radar of late.
Pfizer has already come on board as a partner for the development of iSONEP and was also granted a 'first right of refusal' for ASONEP in the treatment of cancer as well. The partnership agreement came with a significant up-front payment and could be worth as much as nearly half a billion dollars to Lpath, should certain milestones be met and should Pfizer decide to continue the relationship following the completion of the Phase II portion of development.
Additionally, if Pfizer decides to stay on for the duration of iSONEP commercialization, Lpath would be due double digit royalties on sales.
Beyond iSONEP and ASONEP, Lpath is continuing to build a solid pipeline of product candidates based on its ImmuneY2 platform. ImmuneY2 contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders.
Earlier this month Lpath announced a stock offering to raise money to fund Lpathomab, designed to target Lysophosphatidic Acids (LPA) and being developed for the treatment of CNS Disorders, Pain, and Fibrosis.
Lpath is the first company to have brought the technology of targeting bioactive lipids so far in development, and given the multiple billion-dollar markets targeted by this technology, it's safe to assume that this company might make some noise in 2012 - especially with high-profile Pfizer partnership to boast and multiple trial results coming due.
|
